P A LoBue1, K S Moser. 1. Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. pgl5@cdc.gov
Abstract
SETTING: A local tuberculosis control program. OBJECTIVE: To examine treatment completion rates of patients with Mycobacterium bovis disease and compare them with those of patients with M. tuberculosis disease. DESIGN: Retrospective review of data from a tuberculosis surveillance computer database. RESULTS: Data from 167 M. bovis patients and 928 M. tuberculosis patients were examined. Rates of treatment completion were not significantly different (78% vs. 82%, chi2 = 1.60, P = 0.174), although death was more frequent among M. bovis patients (15% vs. 7%). The median time to treatment completion was 94 days longer for M. bovis patients. CONCLUSION: Overall, treatment completion rates of M. bovis and M. tuberculosis patients were comparable, although the death rate was higher for M. bovis patients. The latter finding may be related to a particularly high death rate among HIV-infected M. bovis patients. Therapy duration was longer for M. bovis patients, probably because resistance to pyrazinamide prevented the use of a short-course (6-month) regimen.
SETTING: A local tuberculosis control program. OBJECTIVE: To examine treatment completion rates of patients with Mycobacterium bovis disease and compare them with those of patients with M. tuberculosis disease. DESIGN: Retrospective review of data from a tuberculosis surveillance computer database. RESULTS: Data from 167 M. bovispatients and 928 M. tuberculosispatients were examined. Rates of treatment completion were not significantly different (78% vs. 82%, chi2 = 1.60, P = 0.174), although death was more frequent among M. bovispatients (15% vs. 7%). The median time to treatment completion was 94 days longer for M. bovispatients. CONCLUSION: Overall, treatment completion rates of M. bovis and M. tuberculosispatients were comparable, although the death rate was higher for M. bovispatients. The latter finding may be related to a particularly high death rate among HIV-infected M. bovispatients. Therapy duration was longer for M. bovispatients, probably because resistance to pyrazinamide prevented the use of a short-course (6-month) regimen.
Authors: Borna Müller; Salome Dürr; Silvia Alonso; Jan Hattendorf; Cláudio J M Laisse; Sven D C Parsons; Paul D van Helden; Jakob Zinsstag Journal: Emerg Infect Dis Date: 2013-06 Impact factor: 6.883
Authors: Miriam Bobadilla-del Valle; Pedro Torres-González; Miguel Enrique Cervera-Hernández; Areli Martínez-Gamboa; Brenda Crabtree-Ramirez; Bárbara Chávez-Mazari; Narciso Ortiz-Conchi; Luis Rodríguez-Cruz; Axel Cervantes-Sánchez; Tomasa Gudiño-Enríquez; Carmen Cinta-Severo; José Sifuentes-Osornio; Alfredo Ponce de León Journal: PLoS Negl Trop Dis Date: 2015-09-30
Authors: Salome Dürr; Borna Müller; Silvia Alonso; Jan Hattendorf; Cláudio J M Laisse; Paul D van Helden; Jakob Zinsstag Journal: PLoS Negl Trop Dis Date: 2013-08-29